Ovarian cancer vaccine - Anixa Biosciences/Cleveland Clinic
Latest Information Update: 25 Jan 2024
At a glance
- Originator Cleveland Clinic
- Developer Anixa Biosciences
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 23 Jan 2024 Anixa Biosciences receives a "Decision to Grant" notice from the Japan Patent Office for Ovarian Cancer Vaccines
- 28 Nov 2023 Anixa Biosciences receives "Intention to Grant" notice from the EPO for Ovarian Cancer Vaccines in in European Union
- 03 Oct 2023 Anixa Biosciences has patent protection for ovarian cancer vaccine technology in USA